MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED ADULTS WITH HCV GENOTYPE 1

被引：5
|
作者：
Dore, G. [1 ,2 ]
Knysz, B. [3 ]
Luo, Y. [4 ]
Janczewska, E. [5 ]
Streinu-Cercel, A. [6 ,7 ]
Caruntu, F. A. [6 ]
Motoc, A. [8 ]
Mazur, W. [9 ]
Shaw, D. [10 ]
Tornai, I. [11 ]
Sasadeusz, J. [12 ]
Skoien, R. [13 ]
Sullivan, D. [4 ]
Liu, X. [4 ]
Podsadecki, T. [4 ]
机构：
[1] UNSW Australia, Kirby Inst, Sydney, NSW, Australia
[2] St Vincents Hosp, Sydney, NSW 2010, Australia
[3] Wroclaw Med Univ, Wroclaw, Poland
[4] AbbVie Inc, N Chicago, IL USA
[5] ID Clin, Myslowice, Poland
[6] Natl Inst Infect Dis Prof Dr Matei Bals, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Bucharest, Romania
[8] Hosp Infect Dis Dr Victor Babes, Bucharest, Romania
[9] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland
[10] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[11] Univ Debrecen, Dept Med, Div Gastroenterol, Debrecen, Hungary
[12] Royal Melbourne Hosp, Melbourne, Vic, Australia
[13] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31049-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0847
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [21] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials
    Kieffer, T. L.
    De Meyer, S.
    Bartels, D. J.
    Sullivan, J. C.
    Dierynck, I.
    Adda, N.
    Kwong, A.
    Jacobson, I. M.
    Sherman, K. E.
    Zeuzem, S.
    Picchio, G.
    ANTIVIRAL THERAPY, 2011, 16 : A27 - A27
  • [22] Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
    Ira Jacobson
    Stefan Zeuzem
    Robert Flisiak
    Brygida Knysz
    Stefan Lueth
    Dorota Zarebska-Michaluk
    Ewa Janczewska
    Peter Ferenci
    Moises Diago
    Anna Linda Zignego
    Rifaat Safadi
    Yaacov Baruch
    Dzhamal Abdurakhmanov
    Stephen Shafran
    Dominique Thabut
    Rafael Bruck
    Adrian Gadano
    Alexander James Thompson
    Justin Kopit
    Fiona Mc Phee
    Tracy Michener
    Eric A Hughes
    Philip D Yin
    Stephanie Noviello
    World Journal of Gastroenterology, 2016, 22 (12) : 3418 - 3431
  • [23] COST EFFECTIVENESS OF BOCEPREVIR PLUS PEGINTERFERON ALPHA AND RIBAVIRIN VERSUS TELAPREVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN PREVIOUSLY UNTREATED GENOTYPE I PATIENTS
    Fonseca, M.
    Garran, V
    Araujo, G. T.
    VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
  • [24] Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
    Jacobson, Ira
    Zeuzem, Stefan
    Flisiak, Robert
    Knysz, Brygida
    Lueth, Stefan
    Zarebska-Michaluk, Dorota
    Janczewska, Ewa
    Ferenci, Peter
    Diago, Moises
    Zignego, Anna Linda
    Safadi, Rifaat
    Baruch, Yaacov
    Abdurakhmanov, Dzhamal
    Shafran, Stephen
    Thabut, Dominique
    Bruck, Rafael
    Gadano, Adrian
    Thompson, Alexander James
    Kopit, Justin
    McPhee, Fiona
    Michener, Tracy
    Hughes, Eric A.
    Yin, Philip D.
    Noviello, Stephanie
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (12) : 3418 - 3431
  • [25] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis
    Ascione, Antonio
    De Luca, Massimo
    Melazzini, Mario
    Montilla, Simona
    Trotta, Maria Paola
    Petta, Salvatore
    Puoti, Massimo
    Sangiovanni, Vincenzo
    Messina, Vincenzo
    Bruno, Savino
    Izzi, Antonio
    Villa, Erica
    Aghemo, Alessio
    Zignego, Anna Linda
    Orlandini, Alessandra
    Fontanella, Luca
    Gasbarrini, Antonio
    Marzioni, Marco
    Giannini, Edoardo G.
    Craxi, Antonio
    INFECTION, 2018, 46 (05) : 607 - 615
  • [26] Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir plus /- ribavirin in HCV genotype 1-infected patients with a history of bleeding disorders: Results from phase 3 trials
    Parruti, Giustino
    Macedo, Guilherme
    Baumgarten, Axel
    Nevens, Frederik
    Feld, Jordan J.
    Hezode, Christophe
    Larsen, Lois M.
    Shulman, Nancy
    Vilchez, Regis A.
    Wedemeyer, Heiner
    HEPATOLOGY, 2015, 62 : 754A - 755A
  • [27] Real-world efficacy and safety of ombitasvir, paritaprevir/r plus dasabuvir plus ribavirin in genotype 1b patients with hepatitis C virus cirrhosis
    Preda, Carmen M.
    Popescu, Corneliu P.
    Baicus, Cristian
    Voiosu, Theodor A.
    Manuc, Mircea
    Pop, Corina Silvia
    Gheorghe, Liana
    Sporea, Ioan
    Trifan, Anca
    Tantau, Marcel
    Tantau, Alina
    Ceausu, Emanoil
    Proca, Doina
    Constantinescu, Ileana
    Ruta, Simona M.
    Diculescu, Mircea M.
    Oproiu, Alexandru
    LIVER INTERNATIONAL, 2018, 38 (04) : 602 - 610
  • [28] Preliminary Experience using Telaprevir with Peginterferon and Ribavirin for Treatment of HCV Genotype 1 after Liver Transplantation
    Pungpapong, Surakit
    Murphy, Jennifer L.
    Henry, Tanisha M.
    Ryland, Kristen
    Satyanarayana, Raj
    Rosser, Barry
    Yataco, Maria L.
    Keaveny, Andrew
    HEPATOLOGY, 2012, 56 : 195A - 195A
  • [29] Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir plus Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV
    Saab, Sammy
    Gonzalez, Yuri S.
    Huber, Caroline
    Wang, Alice
    Juday, Timothy
    LIVER INTERNATIONAL, 2016, 36 (04) : 515 - 521
  • [30] Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Kumada, Hiromitsu
    Toyota, Joji
    Okanoue, Takeshi
    Chayama, Kazuaki
    Tsubouchi, Hirohito
    Hayashi, Norio
    JOURNAL OF HEPATOLOGY, 2012, 56 (01) : 78 - 84
12345